KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Recursion Pharmaceuticals (RXRX) Tax Provisions (2023 - 2025)

Historic Tax Provisions for Recursion Pharmaceuticals (RXRX) over the last 3 years, with Q3 2025 value amounting to $3000.0.

  • Recursion Pharmaceuticals' Tax Provisions fell 9820.36% to $3000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$148000.0, marking a year-over-year increase of 9715.22%. This contributed to the annual value of -$1.1 million for FY2024, which is 7225.5% up from last year.
  • According to the latest figures from Q3 2025, Recursion Pharmaceuticals' Tax Provisions is $3000.0, which was down 9820.36% from -$158000.0 recorded in Q1 2025.
  • Over the past 5 years, Recursion Pharmaceuticals' Tax Provisions peaked at $167000.0 during Q3 2024, and registered a low of -$4.1 million during Q4 2023.
  • Over the past 3 years, Recursion Pharmaceuticals' median Tax Provisions value was -$158000.0 (recorded in 2025), while the average stood at -$763571.4.
  • Per our database at Business Quant, Recursion Pharmaceuticals' Tax Provisions soared by 10017.23% in 2024 and then plummeted by 9820.36% in 2025.
  • Recursion Pharmaceuticals' Tax Provisions (Quarter) stood at -$4.1 million in 2023, then surged by 100.17% to $7000.0 in 2024, then tumbled by 57.14% to $3000.0 in 2025.
  • Its last three reported values are $3000.0 in Q3 2025, -$158000.0 for Q1 2025, and $7000.0 during Q4 2024.